Larazotide – (258818-34-7)

Larazotide is an investigational octapeptide drug designed to treat celiac disease by regulating intestinal permeability. Derived from a protein secreted by Vibrio cholerae, larazotide acetate has the amino acid sequence GGVLVQPG. It functions as a zonulin antagonist, blocking zonulin receptors to prevent tight junction disassembly in the intestinal epithelium, thereby reducing intestinal permeability and limiting the passage of gliadin fragments that trigger immune responses in celiac patients.

Clinical trials have shown that larazotide acetate is well-tolerated and may improve gastrointestinal symptoms in celiac patients undergoing gluten challenge. However, it did not significantly affect the lactulose-to-mannitol ratio, a measure of intestinal permeability, compared to placebo. The drug has also demonstrated antiviral activity against the varicella-zoster virus (VZV).

Despite promising results in some studies, Phase 3 clinical trials for larazotide acetate in celiac disease were discontinued by Meters Biopharma in 2022.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Larazotide
https://www.medchemexpress.com/larazotide.html
https://www.medkoo.com/products/25255
https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/larazotide
https://pubmed.ncbi.nlm.nih.gov/34339872/